



The 2nd Virtual Global Congress on
Controversies in Ophthalmology
June 24-25, 2022



FRIDAY, JUNE 24, 2022
15:00-15:55 CET



**CONTROVERSIES IN THE MANAGEMENT OF
DIABETIC MACULAR EDEMA**

SATURDAY, JUNE 25, 2022
13:00-14:00 CET



**PEARLS AND PITFALLS IN MANAGING
EXUDATIVE RETINAL DISEASE**

FOR HEALTHCARE PROFESSIONALS ONLY

Controversies in Ophthalmology (COPHy) Virtual Congress 2022

Friday 24th June 2022

Controversies in the Management of Diabetic Macular Edema

15:00-15:05 CEST **Welcome & introductions**

Anat Loewenstein (Israel)

15:05-15:20 CEST **VEGF is a sufficient target alone to treat DME**

Matias Iglicki (Argentina) and Dinah Zur (Israel)

15:20-15:35 CEST **We do not need to individualize treatment for DME**

Jorge Ruiz Medrano (Spain) and Deepali Varma (UK)

15:35-15:50 CEST **The treatment burden is smaller with intravitreal steroid
injections compared to aVEGF injections**

Patricia Udaondo (Spain) and Amir Rosenblatt (Australia)

15:50-15:55 CEST **Close**

Anat Loewenstein (Israel)

aVEGF, anti-vascular endothelial growth factor; DME, diabetic macular edema; VEGF, vascular endothelial growth factor.

Presentations are in relation to Allergan, an AbbVie company products.

Presenters are consultants to Allergan, an AbbVie company.

Materials developed under Spanish product license. A list of countries with this product/indication is available from ukmedinfo@abbvie.com.

The presentations and materials disseminated in this event include scientific information for educational purposes, intended for healthcare professionals only.

Presentations and materials disclosed during the event are subject to Intellectual Property Rights.

Total or partial reproduction or use of this content requires prior Allergan authorization.

Organized and funded by Allergan, an AbbVie company.

Registration conditions and licenses differ internationally. Adverse events should be reported to your Ministry of Health and local AbbVie office.

Adverse events should be reported. Reporting forms and information can be found at <https://yellowcard.mhra.gov.uk> or via the MHRA Yellow Card app, available in the Google Play or Apple App Stores. Adverse events should also be reported to AbbVie on GEPV@abbvie.com.

Sistema Español de Farmacovigilancia de Medicamentos de Uso Humano: www.notificaRAM.es



ALI-ABBV-220130 Date of preparation: May 2022

Bayer symposium at the Virtual COPHy Global Congress 2022

COPHy

Join us for a series of engaging debates as our expert speakers explore key topics in the management of exudative retinal disease

Pearls and pitfalls in managing exudative retinal disease

Saturday 25 June 2022 | 13:00–14:00 (CEST)

Chair: Dr Baruch Kuppermann

Sessions	Speaker(s)
Welcome and Introductions	Dr Baruch Kuppermann
Is proactive individualised treatment the new standard of care in DME?	Yes: Dr John Kitchens No: Professor Gemmy Cheung
Is real-world experience as important as the pivotal studies in determining a drug's use?	Yes: Mr James Talks No: Dr Patricia Udaondo
Have we arrived at the end of the road for advancements in nAMD treatment?	Yes: Dr Stela Vujosevic No: Dr Aude Ambresin
Live: Panel discussion / audience Q&A	All
Summary of key learnings	Dr Baruch Kuppermann

Learn more about Bayer by
visiting our online channels:



COPHy, Controversies In Ophthalmology. DME, diabetic macular oedema.
nAMD, neovascular age-related macular degeneration.

This symposium is organised and supported by Bayer.

The summary of product characteristics (SmPC) of aflibercept solution for injection as approved by the European Commission for the European Union can be found [here](#). For the product information in other countries, please contact your Bayer representative.

May 2022 | PP-EYL-ALL-0950-1

